MNG590
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.558
- E2F_TARGETS+0.438
- CHOLESTEROL_HOMEOSTASIS+0.434
- MTORC1_SIGNALING+0.434
- PI3K_AKT_MTOR_SIGNALING+0.430
- ADIPOGENESIS+0.426
- PROTEIN_SECRETION+0.425
- GLYCOLYSIS+0.411
- MYC_TARGETS_V1+0.402
- G2M_CHECKPOINT+0.399
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.247
- HEDGEHOG_SIGNALING-0.213
- APICAL_SURFACE-0.178
- KRAS_SIGNALING_DN-0.152
- PANCREAS_BETA_CELLS-0.126
- SPERMATOGENESIS-0.112
- INTERFERON_ALPHA_RESPONSE-0.061
- MYOGENESIS-0.011
- INTERFERON_GAMMA_RESPONSE+0.023
- ALLOGRAFT_REJECTION+0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 46061E4B-5256-42AD-BA9A-FBCEBE92B09A | — | — | 0.903 |
| 2 | 61D1FD4D-F0FF-4D89-B26F-C1102685ED9D | — | — | 0.902 |
| 3 | BS_SHJA4MR0 | high-grade glioma | — | 0.898 |
| 4 | 61496AD6-7265-4D58-87CC-4FEE9723106E | — | — | 0.885 |
| 5 | SRR11296801 | — | — | 0.884 |
| 6 | 52F6F0A9-8D2D-49BC-9B49-E20E5E53561C | — | — | 0.883 |
| 7 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.876 |
| 8 | SRR12696796 | — | — | 0.874 |
| 9 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.871 |
| 10 | SRR10900566 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.558 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.438 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.434 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.434 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.430 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.426 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.425 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.411 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.402 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.399 | Inavolisib | — uncovered |
| HYPOXIA | 0.386 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.375 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.364 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.362 | Inavolisib | — uncovered |
| COMPLEMENT | 0.343 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.342 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.336 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.331 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.311 | Inavolisib | — uncovered |